Glimepiride
- Generic Name
- Glimepiride
- Brand Names
- Duetact, Tandemact
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34N4O5S
- CAS Number
- 93479-97-1
- Unique Ingredient Identifier
- 6KY687524K
- Background
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...
- Indication
Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 36
- Registration Number
- NCT01951339
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 95
- Registration Number
- NCT01910441
A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)
- Conditions
- Interventions
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 65
- Registration Number
- NCT01863667
Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 33
- Registration Number
- NCT01829477
Effects of Vildagliptine and Glimepiride on Glucose Variability
- Conditions
- Interventions
- First Posted Date
- 2013-03-15
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT01812122
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)
- Conditions
- Interventions
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT01769378
- Locations
- 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Somerset West, South Africa
Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male Subjects
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2013-04-23
- Lead Sponsor
- LG Life Sciences
- Target Recruit Count
- 27
- Registration Number
- NCT01768455
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 402
- Registration Number
- NCT01755156
A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
- Conditions
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 329
- Registration Number
- NCT01717313
A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 5570
- Registration Number
- NCT01709305
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.